Assessments (survey data) in this study are designed to sample the symptom burden of patients undergoing adjuvant and neoadjuvant chemotherapy in the hospital. There will be no change in the treatment plan for these patients.
Study Type
OBSERVATIONAL
Enrollment
11
Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assessments: Demographic \& health Trait anxiety Quality of life Nausea Expectations Anxiety \& total mood disturbance Nausea \& vomiting Multiple symptoms
University of Pittsburgh, Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
To determine the extent of symptom burden and quality of life in sarcoma patients receiving AI chemotherapy.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.